• We specialize in small molecule inhibitors, agonists, antagonists and screening libraries!
Search Site
Related Products
MK-4827PARP-1/-2 inhibitor,potent and selective

MK-4827

Catalog No. A3617
Size Price Stock Qty
5mg $137.00 In stock
10mg $231.00 In stock
50mg $778.00 In stock
100mg $1,367.00 In stock

Tel: +1-832-696-8203

Email: sales@apexbt.com

Worldwide Distributors

Sample solution is provided at 25 µL, 10mM.

Quality Control

Chemical structure

MK-4827

Biological Activity

MK-4827 is a potent, selective inhibitor of PARP 1 and PARP 2 with IC50 of 3.8 and 2.1 nM, respectively.
Targets PARP1 PARP2        
IC50 3.8 nM 2.1 nM        

Protocol

Kinase experiment [1]:

Kinase assays

The reaction was conducted as for PARP-1 and PAPP-2 and included 0.3 nM of PARP-2, 4.4 x 105 DPM of [3H]-NAD and 7.5 uM NAD.

Cell experiment [1]:

Cell lines

MDA-MB-436 and CAPAN-1 cell lines, human prostate epithelial (PREC) cells, Human mammary epithelial (HMEC) cells

Preparation method

Soluble in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

0-20000 nM

Applications

In MDA-MB-436 cells carrying BRCA-1 mutations, MK-4827 displayed CC50 = 18 nM, while in CAPAN-1 cells with BRCA-2 mutant, MK-4827 displayed CC50 = 90 nM. In contrast, normal human prostate and mammary epithelial cells were resistant to MK-4827, displaying antiproliferative effects in the micromolar range, thereby demonstrating the very high selective cytotoxicity from these PARP inhibitors in BRCA-1 and -2 mutant cancer cells compared to surrounding tissue.

Animal experiment [2]:

Animal models

Female nude mice (Ncr Nu/Nu) xenograft model

Dosage form

25 mg/kg given twice daily or 50 mg/kg MK-4827 given once daily, oral

Application

The in vivo efficacy of MK-4827 was demonstrated in a BRCA-1 mutant MDA-MB-436 xenograft mode. When tumors reached an average volume of 150 mm3, mice were treated with MK-4827, dosing orally at either 100 mg/kg q.d. or 50 mg/kg b.i.d. Tumor regression was observed with both dosing regimes, and both were well tolerated, with no mortality. Less than 10% body weight loss was seen during the experiment.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1] Jones P, Altamura S, Boueres J, Ferrigno F, et al. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009 Nov 26;52(22):7170-85.

[2] Wang L, Mason KA, Ang KK,Buchholz T,Valdecanas D, Mathur A, Buser-Doepner C, Toniatti C, Milas L. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs. 2012 Dec;30(6):2113-20.

MK-4827 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

MK-4827 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties

Cas No. 1038915-60-4 SDF Download SDF
Synonyms Niraparib; MK 4827; MK4827
Chemical Name 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide
Canonical SMILES C1CC(CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
Formula C19H20N4O M.Wt 320.39
Solubility DMSO Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

Background

MK-4827 is a novel, selective and orally bioavailable PARP1/PARP2 inhibitor with IC50 of 3.8 nM and 2.1 nM, respevctively.MK-4827 has shown great activity against cancer cells with mutant BRCA-1 and BRCA-2; >330-fold selective against PARP3, V-PARP and Tank1 [1].

Poly(ADP-ribose) polymerase-1 (PARP-1) and PARP-2 belong to a family of enzymes (PARP) that, using β-NAD+as a substrate, catalyze poly(ADP-ribosyl)ation of proteins, synthesize and transfer ADP-ribose polymers onto glutamate, aspartate or lysine residues of acceptor proteins, modifying their functional properties. PARP inhibitors compete with NAD+ at the highly conserved enzyme active site, making them new potential therapeutic strategies as chemo- and radio-potentiation and for the treatment of cancers with specific DNA repair defects as single-agent therapies [2].

In vitro: MK-4827displayed excellent PARP 1 and 2 inhibition with IC50 of 3.8 and 2.1 nM, respectively. In a whole cell assay, MK-4827 inhibited PARP activity with EC50 of 4 nM. MK-4827 also inhibited proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10-100 nM range[1].

In vivo: In a variety of human tumor xenografts of differing p53 status,MK-4827 showed high potential to improve the efficacy of radiotherapy,such as Calu-6 (p53 null), A549 (p53 wild-type [wt]) and H-460 (p53 wt) lung cancers and triple negative MDA-MB-231 human breast carcinoma [3].

References:
[1] Jones P1,Altamura S,Boueres J,Ferrigno F, et al.  Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem.2009 Nov 26;52(22):7170-85.
[2] Yelamos J, Farres J, Llacuna L, et al.  PARP-1 and PARP-2: New players in tumourdevelopment[J]. Am J Cancer Res, 2011, 1(3): 328-346.
[3] Wang L1,Mason KA,Ang KK,Buchholz T,Valdecanas D,Mathur A,Buser-Doepner C,Toniatti C,Milas L.  MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs.2012 Dec;30(6):2113-20.